Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emrosi effects on microbial flora in healthy adults
NCT05597462Phase 1Completed
- Sponsor
- Journey Medical Corporation
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rosacea comparing DFD-29 with Placebo (2 arms). Primary endpoints: Changes in the number of colony forming units (CFUs) of microbial species at 16 weeks and Changes in MIC90 of selected colonized microbial species at 16 weeks. Started Sep 2022; status: completed.
02
Drugs
minocycline hydrochloride modified release (DFD-29)
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT05597462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597462.